Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences (NASDAQ: ANIX) announced the issuance of a European patent for its novel ovarian cancer vaccine technology, developed in collaboration with Cleveland Clinic. This patent, titled "Ovarian Cancer Vaccines," targets a specific protein that is present in pre-menopausal women and disappears after menopause. Dr. Amit Kumar emphasized the potential of this vaccine to significantly improve the poor five-year survival rates of ovarian cancer. The company also has a diverse portfolio, including vaccines for breast cancer and a COVID-19 therapeutic program.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm specializing in cancer and infectious disease treatments, announced that CEO Dr. Amit Kumar will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The event, hosted by M Vest LLC and Maxim Group LLC, will feature discussions with industry leaders and presentations from various biotech firms. Anixa aims to highlight its innovative cancer therapeutics, including a unique CAR-T immunotherapy and vaccines for triple-negative breast cancer and ovarian cancer. More details are available at www.anixa.com.
Anixa Biosciences (NASDAQ: ANIX) announced the issuance of its first European patent for CAR-T cancer treatment technology, licensed from The Wistar Institute and developed with Moffitt Cancer Center. The patent, titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," provides protection within the European Union, complementing an existing U.S. patent. Anixa plans to file an IND application for its ovarian cancer CAR-T therapy by the end of Q1 2021, with clinical studies anticipated to start at Moffitt Cancer Center upon FDA clearance.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm focused on cancer and infectious disease treatments, announced Dr. Amit Kumar, CEO, will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will provide an overview of Anixa's business and updates on its various programs. The session will be available on demand starting at 7:00 a.m. ET on March 9, and attendees can join one-on-one meetings with company management. Anixa develops innovative therapies, including cancer immunotherapies and vaccines.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated animal testing for two proprietary compounds that exhibited potential in in vitro studies against COVID-19. CEO Dr. Amit Kumar stated that these compounds will soon be compared to Remdesivir, the only FDA-approved antiviral for COVID-19. The company anticipates completing this proof of concept study within weeks. The compounds target key enzymes of the virus, potentially remaining effective against emerging variants. Anixa aims for future human clinical trials following successful animal testing.
Anixa Biosciences, a biotechnology firm focused on cancer and infectious disease treatments, announced that CEO Dr. Amit Kumar will present at B. Riley's Inaugural Oncology Investor Conference on January 20-21, 2021. Dr. Kumar will participate in a fireside chat to discuss the company's recent achievements and future milestones. The presentation, scheduled for January 21 at 10:30 a.m. PST, will be accessible via live webcast for registered attendees. Anixa's innovative portfolio includes cancer immunotherapy and vaccines for breast and ovarian cancer. More details can be found on Anixa's website.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm specializing in cancer and infectious disease solutions, will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.
CEO Dr. Amit Kumar will discuss key company updates, including FDA approval for human clinical trials of a breast cancer vaccine and advancements in COVID-19 and CAR-T ovarian cancer treatments.
The presentation will be available on-demand starting at 6:00 a.m. ET on January 11, with a 90-day archive accessible thereafter.
Anixa Biosciences (NASDAQ: ANIX) announced FDA clearance for its Investigational New Drug (IND) application for a breast cancer vaccine developed by Cleveland Clinic's Dr. Vincent Tuohy. This innovative vaccine targets the alpha-lactalbumin protein, which is expressed during pregnancy and lactation, aiming to destroy cancer cells before they develop. The initial clinical focus is on Triple Negative Breast Cancer, which is particularly deadly. Funded by the U.S. Department of Defense, this promising trial marks a significant milestone towards the prevention of breast cancer.
Anixa Biosciences, Inc. (NASDAQ: ANIX) reported a breakthrough in its COVID-19 therapeutic program, revealing that its lead compound shows comparable potency to remdesivir, a currently approved antiviral. The compound targets the SARS-CoV-2 enzyme NSP-15, essential for viral replication. Future plans include enhancing the compound's potency and conducting in vivo animal studies. Anixa aims to deliver an orally administered treatment for COVID-19 that could be taken in outpatient settings, addressing a significant gap in current treatment options.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has entered a license agreement with Cleveland Clinic for exclusive rights to develop an innovative ovarian cancer vaccine technology. This vaccine targets anti-mullerian hormone receptor 2 (AMHR2-ED), which reappears in cancerous cells and is seen as a promising target for prevention. Dr. Vincent Tuohy from Cleveland Clinic has been working on this project, aiming to prevent ovarian cancer through immunization. Anixa is also collaborating on a breast cancer vaccine and seeks to enhance its immuno-oncology portfolio.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
